MetLife Investment Management’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $719K | Buy |
40,006
+4,228
| +12% | +$59.1K | ﹤0.01% | 1710 |
|
|
2026
Q1 | $337K | Hold |
35,778
| – | – | ﹤0.01% | 1948 |
|
|
2025
Q4 | $444K | Sell |
35,778
-5,272
| -13% | -$70.1K | ﹤0.01% | 1852 |
|
|
2025
Q3 | $588K | Hold |
41,050
| – | – | ﹤0.01% | 1723 |
|
|
2025
Q2 | $504K | Hold |
41,050
| – | – | ﹤0.01% | 1671 |
|
|
2025
Q1 | $903K | Sell |
41,050
-699
| -2% | -$16.4K | ﹤0.01% | 1422 |
|
|
2024
Q4 | $947K | Buy |
41,749
+2,111
| +5% | +$46.1K | 0.01% | 1446 |
|
|
2024
Q3 | $720K | Buy |
39,638
+22,334
| +129% | +$518K | ﹤0.01% | 1581 |
|
|
2024
Q2 | $504K | Sell |
17,304
-20,063
| -54% | -$595K | ﹤0.01% | 1716 |
|
|
2024
Q1 | $1.32M | Sell |
37,367
-985
| -3% | -$39.4K | 0.01% | 1147 |
|
|
2023
Q4 | $1.67M | Sell |
38,352
-2,246
| -6% | -$88.4K | 0.01% | 1023 |
|
|
2023
Q3 | $1.55M | Sell |
40,598
-2,107
| -5% | -$88.6K | 0.01% | 1019 |
|
|
2023
Q2 | $1.76M | Sell |
42,705
-1,844
| -4% | -$88.8K | 0.01% | 984 |
|
|
2023
Q1 | $2.56M | Sell |
44,549
-1,193
| -3% | -$67.2K | 0.02% | 828 |
|
|
2022
Q4 | $2.56M | Sell |
45,742
-908
| -2% | -$46.2K | 0.02% | 793 |
|
|
2022
Q3 | $1.98M | Buy |
46,650
+137
| +0.3% | +$7.02K | 0.02% | 881 |
|
|
2022
Q2 | $2.51M | Sell |
46,513
-583
| -1% | -$35K | 0.02% | 805 |
|
|
2022
Q1 | $3.03M | Buy |
47,096
+11,796
| +33% | +$777K | 0.02% | 808 |
|
|
2021
Q4 | $2.36M | Buy |
35,300
+356
| +1% | +$24.1K | 0.02% | 808 |
|
|
2021
Q3 | $2.39M | Sell |
34,944
-543
| -2% | -$38.4K | 0.02% | 777 |
|
|
2021
Q2 | $2.42M | Sell |
35,487
-1,120
| -3% | -$79.2K | 0.02% | 791 |
|
|
2021
Q1 | $2.53M | Sell |
36,607
-2,130
| -5% | -$144K | 0.02% | 767 |
|
|
2020
Q4 | $2.51M | Sell |
38,737
-1,791
| -4% | -$96.4K | 0.02% | 716 |
|
|
2020
Q3 | $1.91M | Sell |
40,528
-1,291
| -3% | -$61.4K | 0.02% | 741 |
|
|
2020
Q2 | $1.97M | Buy |
41,819
+910
| +2% | +$44.7K | 0.02% | 720 |
|
|
2020
Q1 | $1.83M | Hold |
40,909
| – | – | 0.02% | 645 |
|
|
2019
Q4 | $2.38M | Sell |
40,909
-382
| -0.9% | -$22.7K | 0.02% | 740 |
|
|
2019
Q3 | $2.48M | Sell |
41,291
-741
| -2% | -$44.1K | 0.03% | 700 |
|
|
2019
Q2 | $2.35M | Sell |
42,032
-87,334
| -68% | -$4.5M | 0.03% | 739 |
|
|
2019
Q1 | $7.21M | Buy |
129,366
+86,257
| +200% | +$4.39M | 0.02% | 720 |
|
|
2018
Q4 | $1.94M | Sell |
43,109
-151
| -0.3% | -$8.29K | 0.02% | 770 |
|
|
2018
Q3 | $2.85M | Sell |
43,260
-1,076
| -2% | -$66.9K | 0.03% | 696 |
|
|
2018
Q2 | $2.86M | Buy |
44,336
+15,286
| +53% | +$947K | 0.03% | 649 |
|
|
2018
Q1 | $1.61M | Hold |
29,050
| – | – | 0.02% | 844 |
|
|
2017
Q4 | $1.39M | Buy |
+29,050
| New | +$1.42M | 0.02% | 899 |
|
Other funds holding IART
RCMNY
PCMI
MetLife Investment Management's IART Position: Q2 2026 in Review
MetLife Investment Management increased its Integra LifeSciences (IART) stake by 12% in Q2 2026, buying an estimated $59.1K and bringing the position to 40,006 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #1710.
MetLife Investment Management first reported a position in IART in Q4 2017 and has held it in 35 quarters since. The position peaked at $7.21M in Q1 2019. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.
- MetLife Investment Management held 40,006 shares of Integra LifeSciences worth $719K as of Q2 2026.
- MetLife Investment Management bought 4,228 Integra LifeSciences shares in Q2 2026, an estimated $59.1K.
- Integra LifeSciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1710 holding.
- MetLife Investment Management first reported a position in Integra LifeSciences in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Integra LifeSciences position peaked at $7.21M in Q1 2019.
- 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.